{"id":"china-approved-bevacizumab","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Proteinuria"},{"rate":"5-15","effect":"Hemorrhage"},{"rate":"5-10","effect":"Thromboembolism"},{"rate":"1-2","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Wound healing complications"},{"rate":"15-20","effect":"Fatigue"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:57:21.093194","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. This inhibits the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, bevacizumab slows tumor progression and can enhance the efficacy of chemotherapy.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:39.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Recurrent glioblastoma"},{"name":"Metastatic renal cell carcinoma"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT05378867","phase":"PHASE3","title":"A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC","status":"UNKNOWN","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2022-08-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":126},{"nctId":"NCT04416035","phase":"PHASE3","title":"A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC","status":"UNKNOWN","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2020-08-17","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer","enrollment":608},{"nctId":"NCT03882424","phase":"PHASE1","title":"A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®","status":"COMPLETED","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2018-06-12","conditions":"Healthy","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"China-approved Bevacizumab","genericName":"China-approved Bevacizumab","companyName":"Zhejiang Teruisi Pharmaceutical Inc.","companyId":"zhejiang-teruisi-pharmaceutical-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}